|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Purpose:</b> MAPK pathway inhibitors targeting BRAF and MEK have shown clinical efficacy in patients with RAF- and/or RAS-mutated tumors.
|
29760222 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
(1) The expression amount of p42.3 in G1 and M phase was higher than that in S and G2 phase; (2) The space coordinate systems of different structural domains of p42.3 protein were established in Matlab7.0 software; (3) The optimal pathway of p42.3 gene in protein regulatory network in gastric cancer is Ras protein, Raf-1 protein, MEK, MAPK kinase, MAPK, tubulin, spindle protein, centromere protein and tumor.
|
23228105 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumors most frequently displayed either TGF-beta- or BMP-suppressed alterations (81.2%), followed by RAF-mediated alterations (78.6%), and mismatch repair defects (38.4%), constituting a total of 24 integrated pathways.
|
18422752 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
|
22763439 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Raf-1 was expressed mainly in alveolar macrophages in normal lung but was focally upregulated in papillary areas of some tumors.
|
10942532 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RAF expression in human astrocytic tumors.
|
19082503 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RAF overexpression correlated statistically with increased tumor size (p=0.052).
|
22110214 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Raf-1 kinase inhibitor protein (RKIP) is a tumor and metastasis suppressor in cancer cells.
|
24392454 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Raf-1 kinase inhibitor protein (RKIP) expression was associated with the onset, development, invasion, and metastasis of numerous tumor types including prostate cancer, melanoma, colorectal cancer, liver cancer, and breast cancer.
|
24420151 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
RAF inhibitor therapy yields significant reductions in tumour burden in the majority of V600E-positive melanoma patients; however, resistance occurs within 2-18 months.
|
24849047 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Raf-1 kinase inhibitor protein (RKIP) plays a critical role in tumor development by regulating cell functions such as invasion, apoptosis and differentiation.
|
25329396 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis.
|
28000790 |
2016 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
A major difference between tumors and mucosa was found, however, in the phosphorylation of Raf-1.
|
8654136 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Abstract Raf-1 kinase inhibitor protein (RKIP) is a tumor and metastasis suppressor that promotes drug-induced apoptosis in cancer cells.
|
23095110 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accumulated experimental and clinical evidence indicates that the complex biochemical mechanisms of RAF kinase signalling account both for the effectiveness of RAF inhibitors and for the various mechanisms of tumour resistance to them.
|
28984291 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After screening several histidine-lysine polymers in complex with Raf-1 siRNA to reduce tumor growth, we further evaluated the efficacy of this siRNA in complex with the optimal histidine-lysine carrier to reduce the tumor growth in vivo.
|
15803144 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All of these tumors were also genotyped for specific point mutational damage affecting p53 (exons 5, 7, and 8; with ACs additionally sequenced for p53 exon 6); 13 tumors for K-ras-2 (exon 1); and 31 tumors for c-raf-1 (exon 15) growth-regulatory genes.
|
8623922 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although RAF inhibitors can produce impressive clinical responses in patients with mutant <i>BRAF</i> tumors, the mechanisms of resistance to these drugs are incompletely characterized.
|
29880583 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among seven proto-oncogenes tested, changes in the copy number of Ha-ras, c-myc and c-raf-1 were found in only seven tumors.
|
2167142 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of cell lines and tumor specimens that lacked paired normal tissue showed a homozygous pattern with the RAF1 probes in all 18 cases.
|
1683566 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of three raf genes previously detected by transfection of tumor DNAs indicated that these genes were activated by recombination in raf intron 7 and encoded fusion proteins containing amino-terminal non-raf sequences.
|
2710120 |
1989 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
As predicted, the opposite effects of Cav-1 on both tumor cell growth and inhibitory RAF phosphorylation were abolished if ERK is depleted.
|
29141593 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B-RAF over-expression was verified by qPCR in pT1, grade III tumors vs. their normal counterparts (p = 0.016). qPCR revealed a significant RKIP reduction in TCC vs. normal tissue (p = 0.002 and p < 0.001 for T1, grade II and Ta-T1, grade III, respectively); All RAF genes were positively correlated among each other (A-RAF/B-RAF, p = 0.003; A-RAF/RAF-1, p < 0.001; B-RAF/RAF-1, p = 0.050), whereas B-RAF was negatively correlated with RKIP in TCC (p = 0.050).
|
20853079 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Based on the evidence of mammalian target of rapamycin mTORC, mTOR Complex; RAS, Rat sarcoma; RAF, rapidly accelerated fibrosarcoma (mTOR) pathway activation in the tumor, targeted therapy was applied resulting in complete remission of disease.
|
26626406 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
BEAS-2B cells transfected with the c-raf-1 and c-myc protooncogenes and cell lines established from the primary tumors expressed major histocompatibility Class II antigen which has been found on small cell lung carcinoma cells.
|
1712250 |
1991 |